Evidence map›Paper›PMID 17457363›Full record

ArticleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2008

Increased expression of a proline-rich Akt substrate (PRAS40) in human copper/zinc-superoxide dismutase transgenic rats protects motor neurons from death after spinal cord injury.

Fengshan Yu, Purnima Narasimhan, Atsushi Saito, Jing Liu, Pak H Chan

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. The Role of Copper Homeostasis in Brain Disease.International journal of molecular sciences · 2022
    Review
  5. Motoneuron-Specific PTEN Deletion in Mice Induces Neuronal Hypertrophy and Also Regeneration after Facial Nerve Injury.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Fengshan YuDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California 94305-5487, USA.
Purnima Narasimhan
Atsushi Saito
Jing Liu
Pak H Chan
Stanford University · US

Funding

Transgenic Animal CoreP50NS014543 · NINDS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI CHAN, PAK H · 1990 to 2007
$8.2M
Reperfusion and Neurovascular Injury in StrokeR01NS025372 · NINDS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI CHAN, PAK H · 1988 to 2015
$5.0M
Cell Death/Survival After Global Cerebral IschemiaR01NS038653 · NINDS · STANFORD UNIVERSITY · PI CHAN, PAK H · 1998 to 2013
$4.5M
OXYGEN RADICALS AND NEURONAL APOPTOSIS IN FOCAL STROKER01NS036147 · NINDS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI CHAN, PAK H · 1997 to 2010
$3.8M
NINDS NIH HHS P50 NS014543NINDS NIH HHS P50 NS14543NINDS NIH HHS R01 NS025372NINDS NIH HHS R01 NS036147NINDS NIH HHS R01 NS038653NINDS NIH HHS R01 NS25372NINDS NIH HHS R01 NS36147NINDS NIH HHS R01 NS38653
6 · The paper itself

Abstract

The serine-threonine kinase, Akt, plays an important role in the cell survival signaling pathway. A proline-rich Akt substrate, PRAS40, has been characterized, and an increase in phospho-PRAS40 (pPRAS40) is neuroprotective after transient focal cerebral ischemia. However, the involvement of PRAS40 in the cell death/survival pathway after spinal cord injury (SCI) is unclear. Liposome-mediated PRAS40 transfection was performed to study whether overexpression of pPRAS40 is neuroprotective. We further examined the expression of pPRAS40 after SCI by immunohistochemistry and Western blot using copper/zinc-superoxide dismutase (SOD1) transgenic (Tg) rats and wild-type (Wt) littermates. We then examined the relationship between PRAS40 and Akt by injection of LY294002, a phosphatidylinositol 3-kinase (PI3K) pathway inhibitor, or Akt inhibitor IV, a compound that inhibits Akt activation after SCI. Our data demonstrated that increased pPRAS40 resulted in survival of more motor neurons compared with control complementary DNA transfection. Phosphorylated PRAS40 increased in the Wt rats after SCI, whereas there was a greater and prolonged increase in the SOD1 Tg rats. Coimmunoprecipitation showed that binding of pPRAS40 with 14-3-3 increased 1 day after SCI in the Wt rats, whereas there was a significant increase in the Tg rats. The inhibitor studies showed that phospho-Akt and pPRAS40 were decreased after injection of LY294002 or Akt inhibitor IV. We conclude that an increase in pPRAS40 by transfection after SCI results in survival of motor neurons, and overexpression of SOD1 in the Tg rats results in an increase in endogenous pPRAS40 and a decrease in motor neuron death through the PI3K/Akt pathway.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAnimals, Genetically ModifiedBrain IschemiaCell DeathChromonesEnzyme ActivationEnzyme InhibitorsGene ExpressionHumansMorpholinesMotor NeuronsNeuroprotective AgentsPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhosphoproteins2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneAdaptor Proteins, Signal TransducingAkt1s1 protein, ratChromonesEnzyme InhibitorsMorpholinesNeuroprotective AgentsPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhosphoproteinsProto-Oncogene Proteins c-aktSOD1 protein, humanSod1 protein, ratSuperoxide DismutaseSuperoxide Dismutase-1

Identifiers

PMID17457363
PMCPMC2167854
OpenAlexW1995786669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.